Xeljanz - direct healthcare professional communication (DHPC)

tofacitinib citrate

Apie

This direct healthcare professional communication (DHPC) contains important information for healthcare professionals prescribing, dispensing or administering the medicine(s). It also includes a communication plan with details of intended recipients and the dissemination date.

Dokumentai

Direct healthcare professional communication (DHPC): Xeljanz (tofacitinib): Initial clinical trial results of increased risk of major adverse cardiovascular events and malignancies (excluding NMSC) with use of tofacitinib relative to TNF— alpha inhibitors

Key facts

• Medicine name:
  Xeljanz
• Active substance:
  tofacitinib citrate
• Therapeutic area (MeSH):
  Arthritis, Rheumatoid
• DHPC type:
  Safety signal
• Human ATC codes:
  L04AA29
• Dissemination date:
  24/03/2021